On a DART-disclosed basis, Curocell's operating loss widened from KRW 21.4 billion in 2022 to KRW 31.1 billion in 2023 and KRW 36.6 billion in 2024, then narrowed to KRW 36.3 billion in 2025. The company recorded losses for four consecutive years from 2022 to 2025.
The net loss attributable to controlling shareholders was KRW 38.9 billion in 2022, KRW 29.6 billion in 2023, KRW 38.2 billion in 2024, and KRW 46.3 billion in 2025, so the loss widened again in 2025.
The net loss including non-controlling interests was disclosed at the same amounts as the controlling-shareholder figure in each year, so no non-controlling interest gap appears.
Net cash used in operating activities rose every year, from -KRW 14.4 billion in 2022 to -KRW 25.3 billion in 2023, -KRW 28.4 billion in 2024, and -KRW 30 billion in 2025.
According to press reports, the company recorded no revenue in 2025, and fixed costs such as GMP facility upkeep, raw materials, R&D, and depreciation were incurred before any sales. On a quarterly basis, the company has posted losses for five consecutive quarters from Q3 2025 to Q3 2026.
The operating loss was KRW 9.19 billion in Q3 2025, KRW 8.71 billion in Q4 2025, KRW 7.8 billion in Q1 2026, KRW 9.74 billion in Q2 2026, and KRW 7.74 billion in Q3 2026, widening in Q2 and narrowing in Q3.
The net loss attributable to controlling shareholders in Q3 2026 was KRW 8.98 billion, narrower than both the prior quarter and the year-earlier quarter. The sum of the controlling-shareholder net losses over the last four quarters, from Q4 2025 to Q3 2026, was KRW 52.8 billion.
Press reports on Q1 2026 indicated selling, general and administrative expenses of KRW 7.8 billion, up from KRW 6.2 billion a year earlier, with R&D expenses of KRW 6.4 billion, equal to 82.4% of SG&A. Even after approval, follow-on clinical and platform development costs are weighing on earnings.
Pre-IPO estimates reportedly projected 2026 revenue of KRW 114.1 billion, but no revenue was recorded in 2025, and actual sales depend on the timing of reimbursement listing.